Degarelix
- Generic Name
- Degarelix
- Brand Names
- Firmagon, Degarelix Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C82H103ClN18O16
- CAS Number
- 214766-78-6
- Unique Ingredient Identifier
- SX0XJI3A11
- Background
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone s...
- Indication
Degaralix is used for the management of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
- Associated Therapies
- -
Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2018-11-28
- Target Recruit Count
- 19
- Registration Number
- NCT02560051
- Locations
- 🇺🇸
UTHealth Memorial Hermann Cancer Center, Houston, Texas, United States
A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT02526784
- Locations
- 🇫🇮
Tampereen yliopistollinen sairaala (there may be other sites in this country), Tampere, Finland
🇫🇷Groupe Hospitalier Pellegrin Tripode (there may be other sites in this country), Bordeaux, France
🇩🇪Universitaetsklinikum Freiburg (there may be other sites in this country), Freiburg, Germany
Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-07-10
- Last Posted Date
- 2018-11-27
- Target Recruit Count
- 4
- Registration Number
- NCT02494713
- Locations
- 🇺🇸
UTHealth Memorial Hermann Cancer Center, Houston, Texas, United States
Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2021-11-12
- Target Recruit Count
- 12
- Registration Number
- NCT02489357
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT02468284
- Locations
- 🇨🇳
Peking University Third Hospital (there may be other sites in this country), Beijing, China
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 163
- Registration Number
- NCT02346253
- Locations
- 🇺🇸
Stanford University, School of Medicine, Stanford, California, United States
Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2019-08-29
- Target Recruit Count
- 20
- Registration Number
- NCT02324998
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge University Hospitals Foundation Trust,, Cambridge, Cambridgeshire, United Kingdom
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 19
- Registration Number
- NCT02278185
- Locations
- 🇺🇸
University of Colorado Health - Poudre Valley Hospital, Fort Collins, Colorado, United States
🇺🇸University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 461
- Registration Number
- NCT02234089
- Locations
- 🇩🇪
Investigational site (there may be other sites in this country), Rottweil, Germany
Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2017-11-27
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT02229253
- Locations
- 🇳🇱
Groene Hart Ziekenhuis (there may be other sites in this country), Gouda, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.